Danny Tomasello wrote -
The company we work for, CIC Plus, is in many ways like a family. One of our family members lost his wife to Triple Negative Breast Cancer in late 2015. She worked very hard to fight it, bring awareness to the subtype of her disease and to raise money to find a cure.
On May 22nd in Chicago, we will continue her fight in the form of participating in 5K, 10K and Half Marathon races in her memory. Please join us in this effort by walking, running, and/or donating to support our efforts!
More about TNBC here: www.tnbcfoundation.org
It is now commonly understood that breast cancer is not one form of cancer, but many different "subtypes" of cancer. These subtypes of breast cancer are generally diagnosed based upon the presence, or lack of, three “receptors” known to fuel most breast cancers: estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2). The most successful treatments for breast cancer target these receptors. Unfortunately, none of these receptors are found in women with triple negative breast cancer. In other words, a triple negative breast cancer diagnosis means that the offending tumor is estrogen receptor-negative, progesterone receptor-negative and HER2-negative, thus giving rise to the name “triple negative breast cancer.”
On a positive note, this type of breast cancer is typically responsive to chemotherapy. Because of its triple negative status, however, triple negative tumors generally do not respond to receptor targeted treatments. Depending on the stage of its diagnosis, triple negative breast cancer can be particularly aggressive, and more likely to recur than other subtypes of breast cancer. TNBC Foundation® is devoted to finding targeted treatment for triple negative breast cancer. With your help, we will find a cure.